Physician profile
Robin E Adams
NPI 1992815070
$2,745.43
in general payments reported to CMS, 2019-2025
14 companies · $780 in 2025
The $780 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $279 · 2021: $307 · 2022: $110 · 2023: $457 · 2024: $397 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,340.58 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $575.70 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $174.97 | 2023-2024 | Tezspire |
| Insmed, INC. | $164.61 | 2023-2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.24 | 2019-2025 | Jascayd |
| Baxter Healthcare | $124.49 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $54.95 | 2024-2025 | Dupixent |
| Novo Nordisk INC | $46.17 | 2023-2025 | Wegovy |
| Electromed, INC. | $42.18 | 2024 | Smartvest |
| Jazz Pharmaceuticals INC. | $32.02 | 2025 | |
| Viatris Specialty LLC | $22.35 | 2025 | Yupelri |
| Lilly USA, LLC | $15.28 | 2025 | |
| Allergan, INC. | $12.05 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.